Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV002247826 | SCV002517068 | benign | not specified | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003093975 | SCV003293768 | uncertain significance | not provided | 2023-07-26 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs374432034, gnomAD 0.02%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 1684734). This variant has not been reported in the literature in individuals affected with ADGRE2-related conditions. This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 725 of the ADGRE2 protein (p.Arg725Gln). |